An Open-Label, Non-Randomized, Single-Center Study to Preliminary Evaluation of Safety and Efficacy of Patients Who Participant in [14C] AC0010 Trail and Subsequent Receiving AC0010 Treatment
Phase of Trial: Phase I
Latest Information Update: 06 Oct 2017
At a glance
- Drugs AC 0100MA (Primary)
- Indications Carcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Hangzhou ACEA Pharmaceutical Research
- 29 Sep 2017 Planned number of patients changed from 6 to 7.
- 07 Sep 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Dec 2017.
- 26 Jun 2017 Planned End Date changed from 1 Aug 2017 to 1 Dec 2017.